Edition:
United Kingdom

Denali Therapeutics Inc (DNLI.OQ)

DNLI.OQ on NASDAQ Stock Exchange Global Select Market

17.94USD
22 Jun 2018
Change (% chg)

$0.94 (+5.53%)
Prev Close
$17.00
Open
$17.19
Day's High
$18.18
Day's Low
$17.13
Volume
254,014
Avg. Vol
114,482
52-wk High
$25.50
52-wk Low
$14.80

Summary

Name Age Since Current Position

Marc Tessier-Lavignec

Chairman of the Board, Co-Founder

Ryan Watts

2016 President, Chief Executive Officer, Co-Founder, Director

Alexander Schuth

Co-Founder, Chief Operating Officer, Head of Corporate Development

Steve Krognes

48 Chief Financial Officer

Carole Ho

Chief Medical Officer

Peter Klein

55 2018 Independent Director

Biographies

Name Description

Marc Tessier-Lavignec

Dr. Marc Tessier-Lavignec is Chairman of the Board, Co-Founder of Denali Therapeutics Inc. Marc is currently President of Stanford University. Prior to his current role, Marc served as President of The Rockefeller University in New York City, where he was also Carson Family Professor and Head of the Laboratory of Brain Development and Repair. Marc has held faculty positions at the University of California, San Francisco, and Stanford University, before joining Genentech, where he served as Executive Vice President of Research and Chief Scientific Officer, overseeing the company’s disease research and drug discovery efforts. He is the recipient of numerous scientific awards, including being elected a member of the National Academy of Science and the National Academy of Medicine. Marc obtained undergraduate degrees from McGill University and Oxford University, where he was a Rhodes Scholar, and a Ph.D. in neurophysiology from University College London.

Ryan Watts

Mr. Ryan Watts is President, Chief Executive Officer, Co-Founder, Director of Denali Therapeutics Inc. Ryan previously served as Director of the Department of Neuroscience at Genentech, where he was employed for 11 years. During his tenure there, he led the company’s entry into neuroscience, building a department and advancing multiple programs for neurological disease from discovery to clinical testing. Ryan’s own laboratory focused on drug discovery for Alzheimer’s disease and on understanding mechanisms of neurodegeneration guided by human genetics. Ryan is also a leader in the development of improved methods for delivering therapeutic antibodies across the blood-brain barrier. He obtained his B.S. from the University of Utah and his Ph.D. in biological sciences from Stanford University.

Alexander Schuth

Mr. Alexander Schuth is Co-Founder, Chief Operating Officer, Head of Corporate Development of Denali Therapeutics Inc. Alex was previously Director and Head Technology and Diagnostics Partnering and, before that, Head of Neuroscience Partnering at Genentech. During his 10-year tenure at Genentech, he held various operational and leadership positions, gaining significant drug development experience and contributing to the growth and success of Genentech’s pipeline. Before joining Genentech, Alex worked for several years in Merrill Lynch’s investment banking group, where his responsibilities included executing IPOs and other equity capital market transactions. Alex holds an M.B.A. from the Wharton School of the University of Pennsylvania and an M.D. from the Charite Medical School at the Humboldt University in Berlin, Germany.

Steve Krognes

Mr. Steve E. Krognes is Chief Financial Officer of the Company. Steve previously worked at Genentech and Roche for twelve years. At Genentech, he served as CFO and as a member of the Executive Committee for six years, where he was responsible for finance, site services and IT. Steve also represented Genentech on the Board and Executive Committee of the California Life Science Association and served as Chairman of the Genentech Access to Care Foundation. At Roche in Switzerland, Steve led the global Mergers & Acquisition team for more than five years. Under Steve’s leadership, the M&A team executed more than 30 transactions worldwide, including the acquisitions of Ventana Medical Systems and Genentech. Steve worked as an investment banker at Goldman Sachs in London, a management consultant at McKinsey in London, and as a venture capitalist in Stockholm. Steve holds an M.B.A. from Harvard Business School, a B.S. in Economics from the Wharton School of the University of Pennsylvania and is a Second Lieutenant in the Royal Norwegian Air Force.

Carole Ho

Dr. Carole Ho is Chief Medical Officer of the Company. She serves as Head of Development. Carole most recently served as Vice President of Genentech Early Clinical Development. In that role, she was responsible for delivery of pivotal trial-ready drug candidates to the Roche / Genentech late-stage development groups in Neurology, Ophthalmology, Immunology, and Infectious Disease. During her 8 year tenure at Genentech, Carole held positions of increasing responsibility across both the early and late stage clinical development groups with development oversight for multiple therapeutic areas and molecules including crenezumab for Alzheimer’s Disease, ocrelizumab for Multiple Sclerosis, Lampalizumab for dry AMD, and the sBLA approval of Rituxan for Wegener’s granulomatosis and microscopic polyangiitis. Carole received her undergraduate degree in Biochemical Sciences from Harvard College and her M.D. from Cornell University. Carole completed her Medical Internship and Neurology residency at Harvard and served as Chief Resident of Neurology at the Massachusetts General Hospital / Brigham and Women’s Hospital. Prior to Genentech, Carole was on Faculty in the Department of Neurology at Stanford University and subsequently a Medical Director at Johnson and Johnson.

Peter Klein

Mr. Peter S. Klein is Independent Director of the Company. Mr. Klein has 25 years of experience as a senior finance executive. He served as Chief Financial Officer of Microsoft Corporation from November 2009 until May 2013 and spent over 11 years at Microsoft. Most recently, he served as Chief Financial Officer of WME, a global leader in sports and entertainment marketing, from January 2014 until June 2014. Mr. Klein holds a B.A. from Yale University and an M.B.A from University of Washington. He currently serves on the board of directors of two publicly traded companies: Apptio Inc. and F5 Networks, Inc.

Basic Compensation

Options Compensation